Defective vasodilatory mechanisms in hypertension: A G-protein-coupled receptor perspective

Current Opinion in Nephrology and Hypertension

Volumn 15, Issue 2, 2006, Pages 135-140

  Feldman, Ross D ^a   Gros, Robert ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Endothelium; G protein coupled receptor; G protein coupled receptor kinase; Hypertension; Vasodilatation

Indexed keywords

CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE; GUANINE NUCLEOTIDE BINDING PROTEIN; NITRIC OXIDE SYNTHASE;

COMPLEX FORMATION; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; HYPERTENSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM; VASODILATATION;

ADENYLATE CYCLASE; ANIMALS; DISEASE PROGRESSION; GENE EXPRESSION REGULATION; HUMANS; HYPERTENSION; PROTEIN-SERINE-THREONINE KINASES; RATS; RECEPTORS, G-PROTEIN-COUPLED; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; VASODILATION;

EID: 33646773571     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mnh.0000214772.96361.ef     Document Type: Review

References (45)

1. Maguire JJ, Davenport AP. Regulation of vascular reactivity by established and emerging GPCRs. Trends Pharmacol Sci 2005; 26:448-454. A very good review of G-protein-coupled receptors involved in the regulation of vascular tone.
2. Feldman RD, Bierbrier GS. Insulin-mediated vasodilation: impairment with increased blood pressure and body mass. Lancet 1993; 342:707-709.
3. Gros R, Borkowski KR, Feldman RD. Human insulin-mediated enhancement of vascular beta-adrenergic responsiveness. Hypertension 1994; 23:551-555.
4. Mallem Y, Holopherne D, Reculeau O, et al. Beta-adrenoceptor-mediated vascular relaxation in spontaneously hypertensive rats. Auton Neurosci 2005; 118:61-67.
5. Schlaich MP, Ahlers BA, Parnell MM, et al. beta-Adrenoceptor-mediated, nitric-oxide-dependent vasodilatation is abnormal in early hypertension: restoration by L-arginine. J Hypertens 2004; 22:1917-1925.
6. Ferro A, Coash M, Yamamoto T, et al. Nitric oxide-dependent beta2-adrenergic dilatation of rat aorta is mediated through activation of both protein kinase A and Akt. Br J Pharmacol 2004; 143:397-403.
7. Gisclard V, Miller VM, Vanhoutte PM. Effect of 17 beta-estradiol on endothelium-dependent responses in the rabbit. J Pharmacol Exp Ther 1988; 244:19-22.
8. Liu SL, Schmuck S, Chorazcyzewski JZ, et al. Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation 2003; 108:2400-2406.
9. Guo X, Razandi M, Pedram A, et al. Estrogen induces vascular wall dilation: mediation through kinase signaling to nitric oxide and estrogen receptors alpha and beta. J Biol Chem 2005; 280:19704-19710.
10. Simoncini T, Mannella P, Fornari L, et al. Genomic and non-genomic effects of estrogens on endothelial cells. Steroids 2004; 69:537-542.
11. Revankar CM, Cimino DF, Sklar LA, et al. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 2005; 307:1625-1630. This is an important paper regarding the discovery of a GPCR (GPR30) which mediates steroid hormone (estrogen) signaling. This study (and the GPR30 receptor) opens up a whole new era of future experiments examining the regulation of vascular tone by GPR30 (and GPR30-like receptors) and the hormones that activate these newly discovered GPCRs.
12. Feldman RD, Gros R. Impaired vasodilator function in hypertension: the role of alterations in receptor-G protein coupling. Trends Cardiovasc Med 1998; 8:297-305.
13. Metaye T, Gibelin H, Perdrisot R, et al. Pathophysiological roles of G-protein-coupled receptor kinases. Cell Signal 2005; 17:917-928. This is a nice general review of structure, function and the role that different GRKs play in human diseases.
14. Gros R, Benovic JL, Tan CM, et al. G-protein-coupled receptor kinase activity is increased in hypertension. J Clin Invest 1997; 99:2087-2093.
15. Gros R, Tan CM, Chorazyczewski J, et al. G-protein-coupled receptor kinase expression in hypertension. Clin Pharmacol Ther 1999; 65:545-551.
16. Gros R, Chorazyczewski J, Meek MD, et al. G-protein-coupled receptor kinase activity in hypertension: increased vascular and lymphocyte G-protein receptor kinase-2 protein expression. Hypertension 2000; 35:38-42.
17. Eckhart AD, Ozaki T, Tevaearai H, et al. Vascular-targeted overexpression of G protein-coupled receptor kinase-2 in transgenic mice attenuates beta-adrenergic receptor signaling and increases resting blood pressure. Mol Pharmacol 2002; 61:749-758.
18. Liu S, Premont RT, Kontos CD, et al. A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension. Nat Med 2005; 11:952-958. This paper demonstrates the important role of GRK2 in regulating endothelial cell signaling, and the effect that this dysregulation in endothelial function has on vascular tone in a model of portal hypertension. This highlights the potential role of GRKs in altering vascular tone in hypertensive models.
19. Keys JR, Zhou RH, Harris DM, et al. Vascular smooth muscle overexpression of G protein-coupled receptor kinase 5 elevates blood pressure, which segregates with sex and is dependent on Gi-mediated signaling. Circulation 2005; 112:1145-1153. Important contribution which demonstrates the role of GRK5 in mediating hypertension and that this association with elevated blood pressure appears to be, in part, gender dependent.
20. Felder RA, Sanada H, Xu J, et al. G protein-coupled receptor kinase 4 gene variants in human essential hypertension. Proc Natl Acad Sci USA 2002; 99:3872-3877.
21. Speirs HJ, Katyk K, Kumar NN, et al. Association of G-protein-coupled receptor kinase 4 haplotypes, but not HSD3B1 or PTP1B polymorphisms, with essential hypertension. J Hypertens 2004; 22:931-936.
22. Kirstein SL, Insel PA. Autonomic nervous system pharmacogenomics: a progress report. Pharmacol Rev 2004; 56:31-52.
23. Leineweber K, Buscher R, Bruck H, et al. Beta-adrenoceptor polymorphisms. Naunyn Schmiedebergs Arch Pharmacol 2004; 369:1-22.
24. Johnson JA, Terra SG. Beta-adrenergic receptor polymorphisms: cardiovascular disease associations and pharmacogenetics. Pharm Res 2002; 19:1779-1787.
25. Bruck H, Leineweber K, Park J, et al. Human beta2-adrenergic receptor gene haplotypes and venodilation in vivo. Clin Pharmacol Ther 2005; 78:232-238. This study is the first to demonstrate the importance of haplotypes of the beta2-adrenergic receptor in mediating altered vascular reactivity in healthy volunteers. This highlights the role that haplotypes of SNPs are crucial to our understanding of the regulation of vascular tone, and the potential impact these genetic variations may have on the development of vascular disease.
26. Ge D, Huang J, He J, et al. beta2-Adrenergic receptor gene variations associated with stage-2 hypertension in northern Han Chinese. Ann Hum Genet 2005; 69:36-44.
27. Lee YW, Oh VM, Garcia E, et al. Haplotypes of the beta2-adrenergic receptor gene are associated with essential hypertension in a Singaporean Chinese population. J Hypertens 2004; 22:2111-2116.
28. Galletti F, Iacone R, Ragone E, et al. Lack of association between polymorphism in the beta2-adrenergic receptor gene, hypertension, and obesity in the Olivetti heart study. Am J Hypertens 2004; 17:718-720.
29. Jia H, Hingorani AD, Sharma P, et al. Association of the G(s)alpha gene with essential hypertension and response to beta-blockade. Hypertension 1999; 34:8-14.
30. Abe M, Nakura J, Yamamoto M, et al. Association of GNAS1 gene variant with hypertension depending on smoking status. Hypertension 2002; 40:261-265.
31. Chen Y, Nakura J, Jin JJ, et al. Association of the GNAS1 gene variant with hypertension is dependent on alcohol consumption. Hypertens Res 2003; 26:439-444.
32. Yamamoto M, Abe M, Jin JJ, et al. Association of a GNAS1 gene variant with hypertension and diabetes mellitus. Hypertens Res 2004; 27:919-924.
33. Siffert W. G protein polymorphisms in hypertension, atherosclerosis, and diabetes. Annu Rev Med 2005; 56:17-28.
34. Lee J, Lee S, Shin S, et al. Association between the GNB3 polymorphism and blood pressure in young Korean men. Med Sci Sports Exerc 2005; 37:1138-1143.
35. Mitchell A, Pace M, Nurnberger J, et al. Insulin-mediated venodilation is impaired in young, healthy carriers of the 825T allele of the G-protein beta3 subunit gene (GNB3). Clin Pharmacol Ther 2005; 77:495-502. This is an important contribution, because it shows that genetic alterations in the G-protein subunit can alter the responsiveness of other vasodilatory pathways, like insulin.
36. Wieland T, Mittmann C. Regulators of G-protein signalling: multifunctional proteins with impact on signalling in the cardiovascular system. Pharmacol Ther 2003; 97:95-115.
37. Roy AA, Baragli A, Bernstein LS, et al. RGS2 interacts with Gs and adenylyl cyclase in living cells. Cell Signal 2006; 18:336-348.
38. Tang KM, Wang GR, Lu P, et al. Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure. Nat Med 2003; 9:1506-1512.
39. Yang J, Kamide K, Kokubo Y, et al. Genetic variations of regulator of G-protein signaling 2 in hypertensive patients and in the general population. J Hypertens 2005; 23:1497-1505. Important contribution regarding genetic variants of RGS2 and the association with hypertension. This adds another level of complexity to hypertension (and blood pressure regulation).
40. Daaka Y, Luttrell LM, Lefkowitz RJ. Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature 1997; 390:88-91.
41. Chesley A, Lundberg MS, Asai T, et al. The beta(2)-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3′-kinase. Circ Res 2000; 87:1172-1179.
42. 2+ influx in cardiomyocytes. Circ Res 2004; 95:1183-1190.
43. Luttrell LM, van Biesen T, Hawes BE, et al. G-protein-coupled receptors and their regulation: activation of the MAP kinase signaling pathway by G-protein-coupled receptors. Adv Second Messenger Phosphoprotein Res 1997; 31:263-277.
44. Shenoy SK, Lefkowitz RJ. Multifaceted roles of beta-arrestins in the regulation of seven-membrane-spanning receptor trafficking and signalling. Biochem J 2003; 375:503-515.
45. Gros R, Ding Q, Chorazyczewski J, et al. The impact of blunted beta-adrenergic responsiveness on growth regulatory pathways in hypertension. Mol Pharmacol 13 October 2005 [Epub ahead of print]. This study demonstrates that impaired beta-adrenergic-mediated vasodilation during hypertension also appears to 'globally' impair beta-adrenergic (Gs)-mediated activation of growth signaling pathways.